Crinetics-Vertex deal clears US antitrust waiting period, other approvals in hand - CRNX News | RalliesCrinetics-Vertex deal clears US antitrust waiting period, other approvals in hand
C
CRNX• Shareholder vote and closing timeline
- The deal still requires Crinetics shareholder approval at an Aug. 28, 2026 special meeting.
- Closing is expected in early September 2026 if shareholders approve.
Deal clears antitrust review and several foreign approvals
- Vertex plans to acquire Crinetics Pharmaceuticals via a merger, leaving Crinetics as a wholly owned Vertex subsidiary.
- The U.S. antitrust review period expired at 12:45 p.m. ET on Aug. 12, 2026.
- Clearances in Austria and Germany were received; Australia clearance was received, pending a waiting period set to end Aug. 27, 2026.
ZSQR
•
